Skip to main content
. 2022 Mar 10;9:157–170. doi: 10.2147/JHC.S353956

Figure 4.

Figure 4

Kaplan–Meier curves for overall survival (OS) of patients with advanced hepatocellular carcinoma who received regorafenib combined with sintilimab (rego-sintilimab) (median OS, 13.4 months; 95% CI, 9.2–17.5) or regorafenib (median OS, 9.9 months; 95% CI, 8.3–11.5; P = 0.023) in a second-line setting.

Abbreviation: CI, confidence interval.